The funding, procurement, storage and distribution of a vaccine present huge challenges to all governments, including New Zealand’s.
Articles on Moderna
Displaying 61 - 69 of 69 articles
Moderna’s shot is far easier to store and distribute than Pfizer’s. But there are concerns neither vaccine performs particularly well for older people.
The recent vaccine trial results certainly look impressive, but here’s how to fully interrogate what they mean.
With COVID-19 cases soaring across the US and worldwide, the need for a vaccine could not be greater. Here’s where we stand on vaccine development, including positive results from Pfizer’s trial.
So-called mRNA vaccines are among the frontrunners in the global race to design a COVID vaccine. But as a new technology, most nations, including Australia, lack the capacity to produce them at scale.
Both Moderna and AstraZeneca have used cutting-edge designs to reduce their vaccines’ development time.
The results from the phase 1 trial are a promising first step in showing that the mRNA vaccine is a viable candidate, but there are unanswered questions and it is still early in the process.
Results from phase 1 trials of a COVID-19 mRNA vaccine created a burst of optimism. But details the company failed to release suggest it is too early to speculate whether the vaccine is effective.
Vaccine development is usually a long process. The coronavirus pandemic is forcing researchers to innovate and test potential vaccines faster than ever before.
Top contributors
-
Professor of Medicine, University of Virginia
-
Research associate, Warren Alpert Medical School, Brown University, Brown University
-
Professor of Microbiology, School of Medicine, University of Washington
-
Associate Professor and ARC Future Fellow, The University of Western Australia
-
Professor of Law, Villanova University
-
Professor, The Children's Hospital at Westmead Clinical School and Sydney Infectious Diseases Institute, University of Sydney
-
Associate professor, Department of Family and Community Medicine, University of Toronto; York University, Canada; University of Sydney
-
Associate Professor, School of Professional Communication, Toronto Metropolitan University
-
Professorial Fellow, University of Canberra
-
Professor of Paediatrics and vaccinologist, Royal Childrens Hospital, University of Melbourne and Murdoch Childrens Research Institute (MCRI); Associate Dean International, University of Melbourne, Murdoch Children's Research Institute
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Part-time lecturer at the Global Health & Social Medicine, Harvard University, and Lecturer at the School of Public Health, College of Health Sciences, University of Liberia
-
Paediatrician and Clinical Senior Lecturer, Children's Hospital Westmead Clinical School, University of Sydney
-
Senior Research Fellow, Population Interventions Unit, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne